Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Spruce Biosciences Inc (SPRB)

Spruce Biosciences Inc (SPRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,238
  • Shares Outstanding, K 41,303
  • Annual Sales, $ 10,090 K
  • Annual Income, $ -47,920 K
  • EBIT $ -43 M
  • EBITDA $ -44 M
  • 60-Month Beta 2.36
  • Price/Sales 1.99
  • Price/Cash Flow N/A
  • Price/Book 0.39
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.94
  • Most Recent Earnings $-0.21 on 11/11/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 186.74% ( +8.04%)
  • Historical Volatility 57.08%
  • IV Percentile 42%
  • IV Rank 13.63%
  • IV High 1,244.83% on 10/10/24
  • IV Low 19.73% on 06/17/24
  • Put/Call Vol Ratio 0.01
  • Today's Volume 286
  • Volume Avg (30-Day) 495
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 15,806
  • Open Int (30-Day) 14,220

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.26
  • Number of Estimates 3
  • High Estimate -0.24
  • Low Estimate -0.28
  • Prior Year -0.23
  • Growth Rate Est. (year over year) -13.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4716 +2.35%
on 11/19/24
0.6080 -20.61%
on 10/24/24
-0.0640 (-11.71%)
since 10/21/24
3-Month
0.4200 +14.93%
on 09/23/24
0.6080 -20.61%
on 10/24/24
+0.0045 (+0.94%)
since 08/21/24
52-Week
0.4112 +17.39%
on 08/12/24
5.9500 -91.89%
on 03/08/24
-0.8873 (-64.77%)
since 11/21/23

Most Recent Stories

More News
S&P Futures Climb Ahead of Key U.S. PPI and Retail Sales Data, Adobe Earnings on Tap

March S&P 500 E-Mini futures (ESH24) are trending up +0.37% this morning as market participants geared up for crucial U.S. PPI and retail sales data while also awaiting quarterly results from software...

ESH24 : 5,101.67s (-1.01%)
DLTR : 65.72 (+4.02%)
TSLA : 340.17 (-0.54%)
INTC : 24.61 (+2.50%)
SKIN : 1.4300 (-4.03%)
ADBE : 504.92 (+1.09%)
DG : 73.86 (+0.81%)
ULTA : 336.17 (-2.07%)
DKS : 197.35 (+1.63%)
ECV.D.DX : 17.010 (+0.18%)
SDF.D.DX : 11.250 (-1.32%)
S : 28.16 (+4.03%)
S&P Futures Tick Higher as Investors Weigh Interest Rate Outlook

September S&P 500 futures (ESU23) are trending up +0.08% this morning after the S&P 500 and Nasdaq closed in the red on Thursday as technology stocks dropped on concerns over the outlook for Apple, while...

ESU23 : 4,491.72s (-0.32%)
AAPL : 229.43 (+0.19%)
SWKS : 85.30 (+2.24%)
QCOM : 156.25 (+1.28%)
AI : 35.35 (+9.24%)
INTC : 24.61 (+2.50%)
MCD : 288.01 (-1.00%)
CCC.LN : 2,224.000 (+1.18%)
DOCU : 80.32 (+1.92%)
ADBE : 504.92 (+1.09%)
SMAR : 55.93 (-0.02%)
SWBI : 13.15 (+1.23%)
Spruce Biosciences to Present Findings on Retrospective Analysis of Completion Rates for CAH Studies at Pediatric Endocrine Society 2023 Annual Meeting

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.4799 (-2.06%)
Spruce Biosciences to Participate in May Investor Conferences

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.4799 (-2.06%)
Spruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate Updates

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.4799 (-2.06%)
Spruce Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.4799 (-2.06%)
Spruce Biosciences Announces $53.6 Million Private Placement Financing

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.4799 (-2.06%)
Spruce Biosciences to Participate in the SVB Securities Global Biopharma Conference

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.4799 (-2.06%)
Spruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.4799 (-2.06%)
Spruce Biosciences (NASDAQ: SPRB) Enters Into Collaboration with Kaken Pharmaceutical to Develop Tildacerfont for CAH in Japan

Spruce Biosciences, Inc. (NASDAQ: SPRB) is engaged as a late-stage biopharmaceutical company, which is focused on the research, development and

SPRB : 0.4799 (-2.06%)

Business Summary

Spruce Biosciences Inc. is a biopharmaceutical company. It focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy which are in clinical stage. Spruce Biosciences Inc. is based in Daly City, California.

See More

Key Turning Points

3rd Resistance Point 0.5418
2nd Resistance Point 0.5257
1st Resistance Point 0.5079
Last Price 0.4799
1st Support Level 0.4740
2nd Support Level 0.4579
3rd Support Level 0.4401

See More

52-Week High 5.9500
Fibonacci 61.8% 3.8342
Fibonacci 50% 3.1806
Fibonacci 38.2% 2.5270
Last Price 0.4799
52-Week Low 0.4112

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar